N-(3-氟苄基)-4-甲基苯胺 | 127598-65-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-氟苄基)-4-甲基苯胺
• 英文名称: N-(3-fluorobenzyl)-4-methylaniline
• 英文别名: N-[(3-fluorophenyl)methyl]-4-methylaniline
• CAS: 127598-65-6
• 化学式: C₁₄H₁₄FN
• mdl: MFCD11147184
• 分子量: 215.27
• InChiKey: NRRGYCBJARDSJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-氟苄基)-4-甲基苯胺 在 水 、 copper(l) chloride 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-((2-((二甲氨基)甲基)-4-甲基苯基)氨基)丙腈
  参考文献：
  名称：

  维尔斯迈尔反应的观察第2部分--苄基-氰基乙基-4-甲基苯胺衍生物的反常反应

  摘要：

  研究了一系列标题苯胺（1）在Vilsmeier条件下与各种取代的苄基的反应。仅全氟苄基衍生物显示出正常的甲酰化，而其他氟衍生物给出了混合的结果，其他取代基仅给出了异常胺（5）和衍生自苄基的醛（6）。

  DOI：

  10.1016/s0040-4020(01)89174-2
• 作为产物：
  描述：

  [1-(3-Fluoro-phenyl)-meth-(E)-ylidene]-p-tolyl-amine 在 sodium tetrahydroborate 作用下， 以98%的产率得到N-(3-氟苄基)-4-甲基苯胺
  参考文献：
  名称：

  维尔斯迈尔反应的观察第2部分--苄基-氰基乙基-4-甲基苯胺衍生物的反常反应

  摘要：

  研究了一系列标题苯胺（1）在Vilsmeier条件下与各种取代的苄基的反应。仅全氟苄基衍生物显示出正常的甲酰化，而其他氟衍生物给出了混合的结果，其他取代基仅给出了异常胺（5）和衍生自苄基的醛（6）。

  DOI：

  10.1016/s0040-4020(01)89174-2

文献信息

• Electrohydrogenation of Nitriles with Amines by Cobalt Catalysis
  作者：Tiantian Wang、Fangfang He、Wei Jiang、Jie Liu

  DOI：10.1002/anie.202316140

  日期：2024.2.12

  efficient electrocatalytic method for earth-abundant cobalt hydride generation through a sequence of cathodic reduction and protonation. The application of this molecular cobalt catalyst allows for electroreductive amination of nitriles to produce various secondary and tertiary amines, as well as deuterium isotope labeling applications from readily available deuterium source.

  本文报道了一种温和有效的电催化方法，通过一系列阴极还原和质子化来产生地球上丰富的氢化钴。这种分子钴催化剂的应用允许对腈进行电还原胺化以生产各种仲胺和叔胺，以及利用容易获得的氘源进行氘同位素标记应用。
• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• 10.1021/jacs.4c02089
  作者：Chen, Kai、Ma, Yixuan、Lin, Yunzhi、Li, Jia-Yue、Shi, Hang

  DOI：10.1021/jacs.4c02089

  日期：——

  with benzene-containing compounds through π-coordination, a property extensively utilized to initiate reactions not typically observed with free arenes. A prime example is nucleophilic aromatic substitution, where ruthenium-complexed aryl halides undergo nucleophilic attack, allowing the direct synthesis of diverse aromatic compounds by displacing halides with nucleophiles. However, this activation relies

  已知钌(II)络合物可通过π配位与含苯化合物形成η 6 -芳烃络合物，这种性质广泛用于引发通常用游离芳烃观察不到的反应。一个典型的例子是亲核芳香取代，其中钌络合的芳基卤化物经历亲核攻击，从而可以通过用亲核试剂取代卤化物来直接合成各种芳香族化合物。然而，这种活化依赖于Ru(II)物质的吸电子效应，并且受到η 6 -芳烃对芳烃交换的阻力的阻碍。在以前对催化的追求中，配体设计的重点集中在促进芳烃交换。在这项研究中，我们将钌活化策略扩展到酚类的反极性取代反应。胺化通过酚和胺之间的直接缩合进行，关键中间体被确定为[bis(η 5 -phenoxo)Ru]，它是由市售钌催化剂原位生成的。与经过充分研究的环戊二烯基 (Cp) 型配体相比，我们证明了 η 5 -phenoxo 基序作为 Cp 的优异替代品，以两种关键方式促进苯酚的胺化：其较少的给电子性质增强了苯酚的氨基化。钌单元的撤回作用，有利于苯酚配合
• 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS
  申请人：Imogai Hassan Julien

  公开号：US20100166655A1

  公开（公告）日：2010-07-01

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20140315903A1

  公开（公告）日：2014-10-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.